See the published version of this preprint at BMC Cancer.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research article
Wilson Eduardo Furlan Matos Alves
Hospital de Cancer de Barretos
Corresponding Author
ORCiD: https://orcid.org/0000-0003-0665-5297
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background Locally advanced breast cancer often undergoes neoadjuvant chemotherapy (NAC), which allows in vivo evaluation of the therapeutic response. The determination of the pathological complete response (pCR) is one way to evaluate the response to neoadjuvant chemotherapy. However, the rate of pCR differs significantly between molecular subtypes and the cause is not yet determined. Recently, the metabolic reprogramming of cancer cells and its implications for tumor growth and dissemination has gained increasing prominence and could contribute to a better understanding of NAC. Thus, this study proposed to evaluate the expression of metabolism-related proteins and its association with pCR and survival rates. Methods The expression of monocarboxylate transporters 1 and 4 (MCT1 and MCT4, respectively), cluster of differentiation 147 (CD147), glucose transporter-1 (GLUT1) and carbonic anhydrase IX (CAIX) was analyzed in 196 locally advanced breast cancer samples prior to NAC. The results were associated with clinical-pathological characteristics, occurrence of pCR, disease-free survival (DFS), disease-specific survival (DSS) and overall survival (OS). Results The occurrence of pCR was higher in the group of patients whith tumors expressing GLUT1 and CAIX than in the group without expression (27.8% versus 13.1%, p = 0.030 and 46.2% versus 13.5%, p = 0.007, respectively). Together with regional lymph nodes staging and mitotic staging, CAIX expression was considered an independent predictor of pCR. In addition, CAIX expression was associated with DFS and DSS (p = 0.005 and p = 0.012, respectively). Conclusions CAIX expression was a predictor of pCR and was associated with higher DFS and DSS in locally advanced breast cancer patients subjected to NAC.
Keywords
Breast cancer, CAIX, glycolytic metabolism, immunohistochemistry, neoadjuvant chemotherapy, pathological complete response.
Figure 1
Figure 2
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Cancer.
Version 2
Posted 20 Nov, 2019
No community comments so far
Editorial decision: Accept
On 11 Nov, 2019
Review #1 received
Received 09 Nov, 2019
Reviewer #1 agreed
On 08 Nov, 2019
Submission checks complete
On 07 Nov, 2019
Editor invited
On 07 Nov, 2019
Editor assigned
On 07 Nov, 2019
Reviewers invited
Invitations sent on 07 Nov, 2019
No comments provided
Editorial decision: Major revision
On 29 Oct, 2019
Review #2 received
Received 19 Oct, 2019
Reviewer #2 agreed
On 16 Oct, 2019
Review #1 received
Received 12 Sep, 2019
Reviewer #1 agreed
On 27 Aug, 2019
Submission checks complete
On 23 Aug, 2019
Reviewers invited
Invitations sent on 23 Aug, 2019
Editor assigned
On 13 Jun, 2019
Editor invited
On 12 Jun, 2019
First submitted
On 11 Jun, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at BMC Cancer.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Wilson Eduardo Furlan Matos Alves
Hospital de Cancer de Barretos
Corresponding Author
ORCiD: https://orcid.org/0000-0003-0665-5297
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Cancer.
Version 2
Posted 20 Nov, 2019
No community comments so far
Editorial decision: Accept
On 11 Nov, 2019
Review #1 received
Received 09 Nov, 2019
Reviewer #1 agreed
On 08 Nov, 2019
Submission checks complete
On 07 Nov, 2019
Editor invited
On 07 Nov, 2019
Editor assigned
On 07 Nov, 2019
Reviewers invited
Invitations sent on 07 Nov, 2019
No comments provided
Editorial decision: Major revision
On 29 Oct, 2019
Review #2 received
Received 19 Oct, 2019
Reviewer #2 agreed
On 16 Oct, 2019
Review #1 received
Received 12 Sep, 2019
Reviewer #1 agreed
On 27 Aug, 2019
Submission checks complete
On 23 Aug, 2019
Reviewers invited
Invitations sent on 23 Aug, 2019
Editor assigned
On 13 Jun, 2019
Editor invited
On 12 Jun, 2019
First submitted
On 11 Jun, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at BMC Cancer.
Background Locally advanced breast cancer often undergoes neoadjuvant chemotherapy (NAC), which allows in vivo evaluation of the therapeutic response. The determination of the pathological complete response (pCR) is one way to evaluate the response to neoadjuvant chemotherapy. However, the rate of pCR differs significantly between molecular subtypes and the cause is not yet determined. Recently, the metabolic reprogramming of cancer cells and its implications for tumor growth and dissemination has gained increasing prominence and could contribute to a better understanding of NAC. Thus, this study proposed to evaluate the expression of metabolism-related proteins and its association with pCR and survival rates. Methods The expression of monocarboxylate transporters 1 and 4 (MCT1 and MCT4, respectively), cluster of differentiation 147 (CD147), glucose transporter-1 (GLUT1) and carbonic anhydrase IX (CAIX) was analyzed in 196 locally advanced breast cancer samples prior to NAC. The results were associated with clinical-pathological characteristics, occurrence of pCR, disease-free survival (DFS), disease-specific survival (DSS) and overall survival (OS). Results The occurrence of pCR was higher in the group of patients whith tumors expressing GLUT1 and CAIX than in the group without expression (27.8% versus 13.1%, p = 0.030 and 46.2% versus 13.5%, p = 0.007, respectively). Together with regional lymph nodes staging and mitotic staging, CAIX expression was considered an independent predictor of pCR. In addition, CAIX expression was associated with DFS and DSS (p = 0.005 and p = 0.012, respectively). Conclusions CAIX expression was a predictor of pCR and was associated with higher DFS and DSS in locally advanced breast cancer patients subjected to NAC.
Figure 1
Figure 2
This is a list of supplementary files associated with this preprint. Click to download.
Loading...